StockWatch
·
Biotechnology: Pharmaceutical Preparations
Corporate ActionJul 6, 2026, 04:07 PM

Abivax Closes $920M Public Offering, Funds Operations to Q4 2029

AI Summary

Abivax S.A. announced the closing of its previously announced underwritten public offering, raising approximately $920.0 million in gross proceeds. The offering included the full exercise of the underwriters' option to purchase additional ADSs, resulting in estimated net proceeds of $874.1 million. The company expects these funds, combined with current cash, to finance its operations into the fourth quarter of 2029.

Key Highlights

  • Abivax closed a public offering of 7,360,000 American Depositary Shares (ADSs).
  • The offering generated aggregate gross proceeds of approximately $920.0 million.
  • Net proceeds from the offering are estimated at approximately $874.1 million.
  • The underwriters' option to purchase additional ADSs was fully exercised.
  • Proceeds, combined with existing cash, will fund operations into Q4 2029.